share_log

BTIG Initiates Coverage On NexImmune with Buy Rating, Announces Price Target of $5

BTIG Initiates Coverage On NexImmune with Buy Rating, Announces Price Target of $5

BTIG以买入评级启动对NexImmune的报道,宣布目标股价为5美元
Benzinga Real-time News ·  2022/06/01 07:30

BTIG analyst Kaveri Pohlman initiates coverage on NexImmune (NASDAQ:NEXI) with a Buy rating and announces Price Target of $5.

BTIG分析师卡维里·波尔曼以买入评级开始对NexImmune(纳斯达克股票代码:NEXI)进行报道,并宣布目标股价为5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发